You continue to cast a wide net in your commentary, not sure why. Your sentiment is BUY?
Now that there has been a first ever approval for a marketable product , partnership opportunities are enhanced . The past is redundant. Why do you keep raising deals that did not eventuate?
Pricing and Orphan status was received post annual meeting- your annual meeting comments are redundant.
I do believe there is a floor , we have Orphan status, we aren't going broke, share price fluctuations irrelevant .
European Pharma will be negotiating for Ryoncil rights, whether that includes Novartis I don't know. Why do you keep raising Novartis, they looked at Remestemcel-l during the ARDS epidemic . That is not front of mind for the company. In fact it is now years old, surprised you don't raise other older deals.
CLBP is at 22 sites, it's on the Clinical trial lists. How many would you like? I think Silviu called for 40? He screwed that up , on that I agree.
Despite your view of Silviu, he is attracting talent to the board. Orphan Status and unbelievable reference pricing for a first in class therapy is in place.
Perhaps consider changing your sentiment ?
Reg
MSB Price at posting:
$1.75 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)